Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Potassium binder lets heart patients get full drug benefits

NCT ID NCT05004363

Disease control Sponsor: St George's, University of London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a drug called Lokelma (SZC) can help people with both chronic kidney disease and heart failure safely reach higher doses of life-saving heart medications (RAAS inhibitors) without dangerous potassium spikes. 112 adults with stable kidney disease and heart failure took either Lokelma or a placebo while doctors gradually increased their heart medication doses. The goal was to see if Lokelma allowed more patients to reach the maximum recommended heart drug dose while keeping potassium levels safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

112 people

The number who actually took part.

Started

Jan 2022

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18 years * Heart failure, clinical or echo confirmed (HFrEF); patients with AF will be included provided the EF can be determined * NYHA class II to IV * Serum potassium 5.0-5.5 mmol/L * Adequate blood pressure (\>90 mm Hg systolic and without postural hypotension; drop of Systolic Blood Pressure \>20 or feeling dizzy with change in posture; exclude patients with symptomatic hypotension due to high doses of ACEi/ARB or MRA unless the clinical condition has improved) * CKD with stable eGFR \<60 ml/min/1.73m2 * None or submaximal dose of ACEi/ARB and/or MRA or both Exclusion Criteria: * • Pregnancy * Active malignancy or infection * BMI\>35 kg/m2 * Poorly controlled sugar HBA1C\> 70 mmol/mmol * Recent ACS * Potassium therapy * Prolonged QT\>550msec, congenital QT syndrome and history of prolong QT requiring drug discontinuation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACE inhibitor induced hyperkalaemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury chronic kidney disease chronic renal failure syndrome heart failure Hyperkalemia pseudohypoaldosteronism pseudohypoaldosteronism type 2 systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACE inhibitor induced hyperkalaemia Chronic kidney diseases Heart failure with reduced ejection fraction Hyperkalemia Mineralocorticoid resistant hyperkalemia

Contacts and locations

Locations

  • St Georges, University of London

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.